Li Judy X, Chen Wei-Chen, Scott John A
a FDA/CBER , OBE, Silver Spring , Maryland , USA.
b FDA/CBER, OBE/DB , Silver Spring , Maryland , USA.
J Biopharm Stat. 2016;26(6):1056-1066. doi: 10.1080/10543406.2016.1226324. Epub 2016 Aug 19.
A common question in clinical studies is how to use historical data from earlier studies, leveraging relevant information into the design and analysis of a new study. Bayesian approaches are particularly well-suited to this task, with their natural ability to borrow strength across data sources. In this paper, we propose an eMAP approach for incorporating historical data into the analysis of clinical studies, and we discuss an application of this method to the analysis of observational safety studies for a class of products for patients with hemophilia A. The eMAP prior approach is flexible and robust to prior-data conflict. We conducted simulations to compare the frequentist operating characteristics of three approaches under different prior-data conflict assumptions and sample size scenarios.
临床研究中的一个常见问题是如何利用早期研究的历史数据,将相关信息应用于新研究的设计和分析。贝叶斯方法特别适合这项任务,因为它们具有从不同数据源借鉴优势的天然能力。在本文中,我们提出了一种将历史数据纳入临床研究分析的eMAP方法,并讨论了该方法在一类甲型血友病患者产品观察性安全性研究分析中的应用。eMAP先验方法灵活且对先验数据冲突具有鲁棒性。我们进行了模拟,以比较在不同先验数据冲突假设和样本量情况下三种方法的频率主义操作特征。